The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

PURPOSE: PARP inhibition is an exciting new anticancer strategy. As the first PARP inhibitor approved for the treatment of advanced BRCA-mutated ovarian cancer, olaparib has proven to be effective in the treatment of several solid tumors. We performed a meta-analysis of published randomized controll...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xiao Xia, Wu, Hong Li, Shi, Hong Yun, Su, Lei, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089112/
https://www.ncbi.nlm.nih.gov/pubmed/30127642
http://dx.doi.org/10.2147/CMAR.S169558

Ejemplares similares

Ejemplares similares